Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STK 012

Next Previous
Drug Profile

STK 012

Alternative Names: STK-012

Latest Information Update: 31 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synthekine
  • Class Antineoplastics; Cytokines; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 20 Apr 2026 Updated efficacy and pharmacodynamics data from a phase Ib/IIa trial in Non-small cell lung cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
  • 26 Feb 2026 Synthekine collaborates for clinical trial with Merck for phase-II SYNERGY-101 trial of STK-012 in combination with Pembrolizumab
  • 07 Nov 2025 Efficacy and adverse event data from a phase Ia/Ib trial in Solid tumours released by Synthekine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top